

Regioselective synthesis of pyrazoles *via* the ring cleavage of 3-substituted *N*-alkylated 3-hydroxyisoindolin-1-ones

Kyu-Tae Chang,^b Yong Hyun Choi,^{†a} Seung-Ho Kim,^a Yong-Jin Yoon^{*c} and Woo Song Lee^{*a}

^a Proteome Research Laboratory, Korea Research Institute of Bioscience and Biotechnology, Taejeon 305-333, Korea

^b Genetic Resources Center, Korea Research Institute of Bioscience and Biotechnology, Taejeon 305-333, Korea

^c Department of Chemistry & Research Institute of Natural Sciences, Gyeongsang National University, Chinju 660-701, Korea

Received (in Cambridge, UK) 18th September 2001, Accepted 22nd November 2001
First published as an Advance Article on the web 13th December 2001


N-Alkyl (Me, Et, ^tPr, ^tBu)-substituted phthalimides **5** were easily transformed to mono-, di-, or tri-substituted pyrazoles **6** *via* a one-pot addition–decyclisation–cyclocondensation process. The regiochemistry of the pyrazole ring was determined by X-ray crystallographic analysis and ¹H NOE experiments.

α -Acetylenic ketones have proven to be very suitable substrates for the synthesis of a wide range of heterocyclic systems.¹ However, the closest literature precedent to regioselective synthesis of pyrazoles using α -acetylenic ketones has been independently studied by the groups of Sabri,² Linderman,³ and Giacomelli.⁴ Regioselective syntheses of 2,3- or 1,3-substituted pyrazoles are of considerable interest to heterocyclic chemistry. In general, well-designed β -diketones (or diketo esters) as the precursors and a 1,3-dipolar cycloaddition process have been utilised to produce many pyrazole compounds.⁵ However, unsymmetric 1,3-diketones (or diketo esters) give a mixture of two regioisomers in a ratio which depends on the nature of 1,3-diketones (or diketo esters).^{5e} Thus, we designed a regioselective synthetic method for the preparation of mono-, di-, or tri-substituted pyrazoles according to methodology based on a hypothetical pathway shown in Scheme 1. Regioselective pyrazole formation involves nucleophilic addition of lithium acetylide onto the *N*-substituted phthalimides **1** to give the keto tautomers **3** of alkynyl-substituted hydroxyisoindolines **2**. Then, α -acetylenic ketones of type **3** may regioselectively react with a variety of hydrazines to produce 2,3-disubstituted pyrazoles **4**. Here, we describe a facile construction method of 2,3-disubstituted pyrazoles **6** employing a one-pot addition–decyclisation–cyclocondensation process.

Results and discussion

The requisite substrates **1** were prepared easily by the usual method from commercially available phthalic anhydride and phthalimide. Subsequently, we investigated a one-pot addition–decyclisation–cyclocondensation process as depicted in Scheme


1. The results are summarised in Table 1. The typical procedure is as follows: to a solution of lithium phenylacetylide (or *p*-tolylacetylide), which was prepared by treatment of *n*-BuLi with phenylacetylene (or *p*-tolylacetylene) in THF, was added a solution of **5a** in THF at 0 °C. After the starting material **5a** had disappeared, the reaction mixture was quenched by addition of H₂O and evaporated to give a residue that was dissolved in EtOH. A solution of hydrazine monohydrate in EtOH was then added and refluxed for 1 h to obtain the pyrazoles **6a-1** and **6a-2** in 74 and 70% yields, respectively. Similar reactions of **5b** and **5c** with lithium phenylacetylide, H₂O and hydrazine monohydrate under reflux conditions gave the pyrazoles **6b** and **6c** in very low yields, respectively. However, *N*-*tert*-butylphthalimide **5d** was easily converted to pyrazole **6d-1** under the mild reaction conditions in excellent yield. We then realized that the size of the *N*-substituted groups on **5** influences the ring cleavage of the C₃–N₂ bond of 3-alkynyl-3-hydroxyisoindoline, which affords the α -acetylenic ketone intermediate. In order to investigate the limitation and scope of a one-pot addition–decyclisation–cyclocondensation process, the reaction of **5d** with organometallic agents was carried out to produce the keto tautomer ynones of 3-hydroxyisoindolines *in situ*. Interestingly, **5d** was treated with lithium phenylacetylide, H₂O and methylhydrazine to give 2,3-disubstituted pyrazole **6d-2** as the sole product in high regioselectivity and yield. The reaction of **5d** with ethynylmagnesium bromide, H₂O and hydrazine monohydrate proceeded smoothly to give pyrazole **6d-3**. Compound **5d** was also treated with lithium (trimethylsilyl)acetylide under similar conditions to give the same desilylated pyrazole **6d-3** in good yield, which was identical to **6d-3** that was obtained by the reaction with ethynylmagnesium bromide. Similar treatment of **5d** with lithium *p*-tolylacetylide, H₂O and various substituted hydrazine derivatives afforded regioselectively the corresponding 2,3-disubstituted pyrazoles **6d-4**, **6d-5** and **6d-6** in good yields, respectively (Table 1).

























Scheme 1

[†] Present address: Department of Chemistry, Korea Advanced Institute of Science and Technology, Taejeon 305-701, Korea.

Table 1 Regioselective synthesis of pyrazoles **6** via ring cleavage of **5** by one-pot decyclization–cyclocondensation^a



Substrates	Conditions ^b	Products ^c	Yield (%) ^d
	R ² = Ph R ³ = H, reflux 1 h		74
	R ² = <i>p</i> -tolyl R ³ = H, reflux 30 min		70
	R ² = Ph R ³ = H, reflux 3 h		6
	R ² = Ph R ³ = H, reflux 3 h		26
	R ² = Ph R ³ = H, rt 10 min		92
	R ² = Ph R ³ = Me, rt 10 min		95
	R ² = H R ³ = H, rt 5 min		72
	R ² = TMS R ³ = H, rt 5 min		96
	R ² = <i>p</i> -tolyl R ³ = H, rt 15 min		95
	R ² = <i>p</i> -tolyl R ³ = Ph, reflux 2 h		87
	R ² = <i>p</i> -tolyl R ³ = (<i>p</i> -NO ₂)Ph, reflux, 5 h		71

^a 5.0 equiv. of hydrazine hydrate and 2.0 equiv. of methyl-, phenyl-, and *p*-nitrophenylhydrazines were used. ^b Reaction time with hydrazine derivatives. ^c The structure and position of substitution were determined by their characteristic data and NOE experiments. ^d Isolated yields.

In order to compare the reactivity with *N*-*tert*-butylphthalimide **5d**, the reactions of *N*-methyl-, ethyl- and isopropylphthalimides **5a–c** with lithium methylacetylide, H₂O and phenyl- (or 4-nitrophenyl-) hydrazine were attempted under reflux conditions. However, these reactions resulted in 95, 97 and 97% recovery of the starting materials **5a–c**. In contrast, we could also isolate 3-hydroxyisoindoline **7** (R¹ = *t*-Bu, R² = Ph) and α -acetylenic ketone **8** (R¹ = *t*-Bu, R² = Ph) in 65 and 22% yields, respectively. When either **7** or **8** was treated with hydrazine monohydrate, the same pyrazole **6d-1** was produced in an excellent yield. Also, after treating the pure hydroxy lactam **7** with bases such K₂CO₃, Et₃N and DMAP in THF, the reaction mixture was subjected to the usual method to give a 3 : 1 ratio of the ring–chain tautomers **7** and **8**. Thus, this characteristic reactivity of **5a–c** vs. that of **5d** may be explained in terms of a steric effect between the *N*-substituted groups and the 3-alkynyl groups of the *N*-alkylated 3-alkynyl-3-hydroxyisoindoline intermediates. In all of the pyrazole ring formations, cleavage of the ring at the C₃–N₂ bond of the 3-hydroxyisoindoline *N*-substituted with a *tert*-butyl group turned out to be preferable to that at the C₃–N₂ bond of 3-hydroxyisoindoline *N*-substituted with methyl, ethyl and isopropyl groups.

The structures of **6** were determined on the basis of their characteristic spectroscopic data. In particular, the structure of **6d-3** was determined by X-ray crystallographic analysis (Fig. 1).[‡] The position of the N₂-4-nitrophenyl group of **6d-6** was





Fig. 1 X-Ray crystal structure of **6d-3**.

readily established by ¹H NOE experiments. Irradiation of the phenyl protons of the N₂-4-nitrophenyl group resulted in a 1.56% nuclear Overhauser enhancement of the phenyl proton of the C₃-2-*tert*-butylbenzamide of the pyrazole ring, but not in a ¹H NOE with the C₄-proton of the pyrazole ring. Moreover, irradiation of the phenyl protons of the C₅-*p*-tolyl group showed a 9.48% NOE with the C₄-proton of the pyrazole ring, but no ¹H NOE with the protons of the N₂-4-nitrophenyl group.

The regiochemical outcome may be rationalized according to Sabri's results² as shown in Scheme 2. Thus, the less sterically hindered unsubstituted nitrogen attacks the β -position of the ynone species **8**, generated *in situ*, to give a β -hydrazine-substituted alkenone **9**, in which the substituted nitrogen is brought into close proximity to the carbonyl carbon allowing rapid completion of the cyclization with expulsion of water to

[‡] CCDC reference number 172539. See <http://www.rsc.org/suppdata/p1/b1/b108485m/> for crystallographic files in .cif or other electronic format.



give predominantly the 2,3-disubstituted pyrazoles. As a result, the regiochemical preference in this addition depends on steric, electronic and mechanistic factors.

In conclusion, we have found that an *N*-*tert*-butyl group is the best for producing the α -acetylenic ketone intermediate by ring cleavage at the C₃-N₂ bond of 3-hydroxyisoindoline to give the 2,3-disubstituted pyrazole. These species should be valuable for novel 5- or 6-membered heterocycles, such as isoxazole,⁷ isothiazole⁸ and quinoline⁹ derivatives.

Experimental

General

Mps were measured on a Thomas-Hoover capillary apparatus and are uncorrected. Proton and carbon magnetic resonance spectra were measured downfield relative to tetramethylsilane in CDCl₃ unless otherwise noted (value in ppm); coupling constants *J* are reported in hertz; ¹H NMR, ¹³C NMR and ¹H NOE experiments were conducted on Bruker AVANCE 300, 400 and FTNMR-DRX 500 spectrometers. Infrared spectral data were obtained on Hitachi 270–50 and EQUINOX55 spectrometers. Elemental analyses were performed with a Perkin Elmer 240C. X-Ray diffraction data were obtained with a Rigaku RAXIS-RAPID Imaging Plate diffractometer with graphite monochromated Mo-K α radiation. Open column chromatography was carried out on silica gel 60 (70–230 mesh, Merck).

N-Methyl-2-(5-phenyl-2*H*-pyrazol-3-yl)benzamide (6a-1): typical procedure

To a solution of lithium phenylacetylide, which was prepared by treatment of *n*-BuLi (1.40 ml, 2.23 mmol, 1.6 M in hexane solution) with phenylacetylene (245.14 μ l, 2.23 mmol) in THF (10 ml) was added a solution of **5a** (300 mg, 1.86 mmol) in THF (10 ml) at 0 °C. After 5 min, the reaction mixture was quenched by addition of H₂O (0.1 ml) and evaporated to give the residue, which was dissolved in EtOH (5 ml) and then a solution of hydrazine monohydrate (676.08 μ l, 11.15 mmol, 80% in H₂O) in EtOH (5 ml) was added at room temperature. After being refluxed for 1 h, the reaction mixture was cooled to room temperature and evaporated under reduced pressure to give the residue, to which was added H₂O (10 ml) and which was then extracted with EtOAc. The combined organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and evaporated to give the crude product. Purification by flash column chromatography on silica gel [EtOAc–hexane (2 : 1)] gave the pure **6a-1** (381 mg, 74%) as colorless prisms, mp 134–136 °C (CH₂Cl₂–hexane); IR (KBr) 3260, 3000 and 1650 cm⁻¹; δ_{H}

(CDCl₃, 500 MHz) 2.82 (3H, d, *J* 4.8), 6.35 (1H, d, *J* 4.5), 6.71 (1H, s), 7.30–7.32 (2H, m), 7.33–7.42 (3H, m), 7.45 (1H, dd, *J* 1.1, 7.7), 7.59 (1H, dd, *J* 0.6, 7.2) and 7.74 (2H, dd, *J* 1.0, 7.2) (Found: C, 73.80; H, 5.52; N, 15.38. C₁₇H₁₅N₃O requires C, 73.63; H, 5.45; N, 15.15%).

N-Methyl-2-(5-*p*-tolyl-2*H*-pyrazol-3-yl)benzamide (6a-2).

Compound **6a-2** was obtained under similar reaction conditions, starting from **5a** (300 mg, 1.86 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 1)] to give pure **6a-2** (379 mg, 70%) as colorless prisms, mp 152–154 °C (CH₂Cl₂–hexane); IR (KBr) 3250 and 1650 cm⁻¹; δ_{H} (CDCl₃, 500 MHz) 2.35 (3H, s), 2.79 (3H, d, *J* 4.9), 6.37 (1H, d, *J* 4.8), 6.66 (1H, s), 7.16 (2H, d, *J* 7.9), 7.28 (1H, dt, *J* 0.6, 7.4), 7.38 (1H, dt, *J* 1.1, 7.5), 7.42 (1H, d, *J* 10.6), 7.56 (1H, d, *J* 7.7) and 7.60 (2H, d, *J* 8.0); δ_{C} (CDCl₃, 125 MHz) 21.7, 27.3, 102.5, 125.9, 128.5, 128.6, 129.1, 129.2, 129.3, 129.9, 130.6, 135.6, 138.3, 146.2, 149.6 and 171.8 (Found: C, 74.38; H, 5.59; N, 14.38. C₁₈H₁₇N₃O requires C, 74.20; H, 5.88; N, 14.42%).

N-Ethyl-2-(5-phenyl-2*H*-pyrazol-3-yl)benzamide (6b).

Compound **6b** was obtained under similar reaction conditions, starting from **5b** (207 mg, 1.18 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 1)] to give pure **6b** (21 mg, 6%) as colorless prisms, mp 148–149 °C (CH₂Cl₂–hexane); IR (KBr) 3250 and 1639 cm⁻¹; δ_{H} (CDCl₃, 300 MHz) 1.06 (3H, t, *J* 7.2), 3.35 (2H, q, *J* 7.2), 6.07 (1H, s), 6.75 (1H, s) and 7.30–7.78 (9H, m) (Found: C, 74.09; H, 5.92; N, 14.27. C₁₈H₁₇N₃O requires C, 74.20; H, 5.88; N, 14.42%).

N-Isopropyl-2-(5-phenyl-2*H*-pyrazol-3-yl)benzamide (6c).

Compound **6c** was obtained under similar reaction conditions, starting from **5c** (198 mg, 1.05 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 1)] to give pure **6c** (85 mg, 26%) as colorless prisms, mp 197–198 °C (CH₂Cl₂–hexane); IR (KBr) 3306, 3063, 2975 and 1632 cm⁻¹; δ_{H} (CDCl₃, 400 MHz) 1.12 (6H, d, *J* 6.6), 4.19 (1H, m), 5.77 (1H, d, *J* 7.6), 6.78 (1H, s) and 7.31–7.80 (9H, m) (Found: C, 74.89; H, 6.40; N, 13.59. C₁₉H₁₉N₃O requires C, 74.73; H, 6.27; N, 13.76%).

N-*tert*-Butyl-2-(5-phenyl-2*H*-pyrazol-3-yl)benzamide (6d-1).

Compound **6d-1** was obtained starting from **5d** (300 mg, 1.48 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane, (1 : 1)] to give pure **6d-1** (435 mg, 92%) as colorless prisms, mp 179–180 °C (CH₂Cl₂–hexane); IR (KBr) 3431, 3209, 3038, 2981 and 1636 cm⁻¹; δ_{H} (CDCl₃, 500 MHz) 1.34 (9H, s), 5.76 (1H, s), 6.78 (1H, s), 7.30–7.36 (2H, m), 7.39–7.45 (3H, m), 7.49 (1H, d, *J* 7.6), 7.62 (1H, d, *J* 7.6) and 7.80 (2H, d, *J* 7.3) (Found: C, 75.06; H, 6.70; N, 13.50. C₂₀H₂₁N₃O requires C, 75.21; H, 6.63; N, 13.16%).

N-*tert*-Butyl-2-(2-methyl-5-phenyl-2*H*-pyrazol-3-yl)benzamide (6d-2).

Compound **6d-2** was obtained under similar reaction conditions, starting from **5d** (300 mg, 1.48 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 2)] to give pure **6d-2** (469 mg, 95%) as colorless prisms, mp 126–127 °C (CH₂Cl₂–hexane); IR (KBr) 3228, 3042, 2975, 1656 and 1545 cm⁻¹; δ_{H} (CDCl₃, 300 MHz) 1.31 (9H, s), 3.91 (3H, s), 5.78 (1H, br s), 6.20 (1H, s) and 7.32–7.77 (9H, m); δ_{C} (CDCl₃, 75 MHz) 28.5, 37.5, 51.5, 106.5, 125.6, 127.9, 128.2, 128.6, 128.7, 129.3, 129.4, 130.4, 130.9, 137.2, 144.5, 149.6 and 169.0 (Found: C, 75.58; H, 7.03; N, 12.48. C₂₁H₂₃N₃O requires C, 75.65; H, 6.95; N, 12.60%).

N-*tert*-Butyl-2-(2*H*-pyrazol-3-yl)benzamide (6d-3).

Compound **6d-3** was obtained under similar reaction conditions, starting from **5d** (300 mg, 1.48 mmol). The crude product was

purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 1)] to give pure **6d-3** (346 mg, 96%) as colorless prisms, mp 189–190 °C (CH₂Cl₂–hexane); IR (KBr) 3146, 2964 and 1633 cm⁻¹; δ_{H} (CDCl₃, 500 MHz) 1.37 (9H, s), 5.70 (1H, br s), 6.53 (1H, d, *J* 1.7), 7.37–7.62 (5H, m) and 11.64 (1H, br s) (Found: C, 69.30; H, 7.18; N, 17.50. C₁₄H₁₇N₃O requires C, 69.11; H, 7.04; N, 17.27%).

***N*-tert-Butyl-2-(5-*p*-tolyl-2*H*-pyrazol-3-yl)benzamide (6d-4).** Compound **6d-4** was obtained under similar reaction conditions, starting from **5d** (300 mg, 1.48 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 3)] to give pure **6d-4** (469 mg, 95%) as yellow prisms, mp 181–183 °C (CH₂Cl₂–hexane); IR (KBr) 3260, 3100, 3000 and 1655 cm⁻¹; δ_{H} (CDCl₃, 500 MHz) 1.33 (9H, s), 2.38 (3H, s), 5.77 (1H, br s), 6.75 (1H, s), 7.21 (2H, d, *J* 7.8), 7.35 (1H, t, *J* 7.5), 7.43 (1H, t, *J* 7.4), 7.50 (1H, dd, *J* 0.9 and 7.6), 7.61 (1H, d, *J* 7.6) and 7.68 (2H, d, *J* 7.9) (Found: C, 75.85; H, 7.08; N, 12.83. C₂₁H₂₃N₃O requires C, 75.65; H, 6.95; N, 12.60%).

***N*-tert-Butyl-2-(2-phenyl-5-*p*-tolyl-2*H*-pyrazol-3-yl)benzamide (6d-5).** Compound **6d-5** was obtained under reflux conditions, starting from **5d** (300 mg, 1.48 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 2)] to give pure **6d-5** (527 mg, 87%) as yellow prisms, mp 67–68 °C (CH₂Cl₂–hexane); IR (KBr) 3420, 3320, 3060, 2980 and 1660 cm⁻¹; δ_{H} (CDCl₃, 400 MHz) 1.29 (9H, s), 2.36 (3H, s), 6.89 (1H, s), 7.14 (1H, d, *J* 7.6), 7.24 (2H, d, *J* 8.0), 7.29–7.49 (7H, m), 7.62 (1H, br s) and 7.74 (2H, d, *J* 8.0); δ_{C} (CDCl₃, 100 MHz) 21.3, 28.5, 51.5, 106.3, 123.8, 125.7, 127.0, 128.5, 128.8, 129.2, 129.4, 129.9, 130.0, 131.0, 137.5, 137.9, 139.5, 142.0, 152.0 and 166.6 (Found: C, 79.29; H, 6.48; N, 10.12. C₂₇H₂₇N₃O requires C, 79.19; H, 6.65; N, 10.26%).

***N*-tert-Butyl-2-[2-(4-nitrophenyl)-5-*p*-tolyl-2*H*-pyrazol-3-yl]benzamide (6d-6).** Compound **6d-6** was obtained under reflux conditions, starting from **5d** (300 mg, 1.48 mmol). The crude product was purified by flash column chromatography on silica gel [EtOAc–hexane (1 : 2)] to give pure **6d-6** (477 mg, 71%) as yellow needles, mp 169–170 °C (CH₂Cl₂–hexane); IR (KBr) 3390, 3000, 2900, 1660 and 1600 cm⁻¹; δ_{H} (CDCl₃, 400 MHz) 1.17 (9H, s), 2.39 (3H, s), 5.41 (1H, br s), 6.80 (1H, s), 7.25 (2H, d, *J* 4.9), 7.33 (1H, dd, *J* 1.2, 5.0), 7.50 (4H, m), 7.66 (1H, dd, *J* 1.1, 5.3), 7.78 (2H, d, *J* 6.0) and 8.10 (2H, d, *J* 6.7); δ_{C} (CDCl₃, 100 MHz) 21.3, 28.6, 51.7, 107.7, 123.1, 124.5, 125.9, 128.2, 128.6, 129.3, 129.5, 129.9, 130.4, 130.7, 137.7, 138.6, 142.9, 144.5, 145.5, 153.3 and 166.6 (Found: C, 71.48; H, 5.85; N, 12.42. C₂₇H₂₆N₄O₃ requires C, 71.35; H, 5.77; N, 12.33%).

Preparation of compounds 7 and 8

To a solution of *N*-tert-butylphthalimide **5d** (800 mg, 3.94 mmol) in THF (10 ml) was added a solution of lithium phenylacetylide which was prepared by treatment of phenylacetylene (519.4 μ l, 4.73 mmol) with *n*-BuLi (2.96 ml, 4.73 mmol, 1.6 M in hexane solution) in THF (10 ml) at 0 °C under a N₂ atmosphere. After being stirred for 20 min, the reaction mixture was treated with H₂O (0.1 ml) and then extracted with EtOAc. The combined organic layer was washed with brine, dried over anhydrous MgSO₄ and filtered. The filtrate was evaporated *in vacuo* to afford the crude products **7** and **8**, which were purified by flash column chromatography on silica gel [EtOAc–hexane

(1 : 3)] to give the pure products **7** (780 mg, 65%) and **8** (264 mg, 22%), respectively.

2-*N*-tert-Butyl-3-hydroxy-3-phenylethynylisoindolin-1-one (7). Colorless prisms, mp 148–150 °C (CH₂Cl₂–hexane); IR (KBr) 3300, 2240 and 1680 cm⁻¹; δ_{H} (CDCl₃, 500 MHz) 1.76 (9H, s), 3.78 (1H, s), 7.32 (3H, m), 7.42 (3H, m), 7.55 (1H, t like, *J* 7.4) and 7.66 (2H, dd, *J* 7.5, 7.6); δ_{C} (CDCl₃, 125 MHz) 28.74, 56.79, 84.11, 85.41, 86.80, 121.80, 122.96, 128.39, 129.07, 129.87, 130.50, 131.62, 132.64, 146.68 and 167.68 (Found: C, 78.48; H, 6.40; N, 4.37. C₂₀H₁₉NO₂ requires C, 78.66; H, 6.27; N, 4.59%).

***N*-tert-Butyl-2-(3-phenylpropynoyl)benzamide (8).** Colorless prisms, mp 168–170 °C (CH₂Cl₂–hexane); IR (KBr) 3350, 2255 and 1655 cm⁻¹; δ_{H} (CDCl₃, 500 MHz) 1.47 (9H, s), 5.60 (1H, br), 7.39–8.10 (8H, m) and 8.11 (1H, dd, *J* 1.0, 7.4); δ_{C} (CDCl₃, 125 MHz) 28.70, 52.13, 87.78, 93.68, 120.07, 128.26, 128.66, 129.34, 130.89, 131.12, 132.82, 133.18, 135.62, 138.88, 168.42 and 178.28 (Found: C, 78.80; H, 6.38; N, 4.42. C₂₀H₁₉NO₂ requires C, 78.66; H, 6.27; N, 4.59%).

Acknowledgements

This work was supported by Korea Research Foundation Grant (KRF-2000–015–DP0281). The authors express also their appreciation to Dr M. Shiro (Rigaku Corporation) for his valuable X-ray analysis.

References

- (a) D. Obrecht, *Helv. Chim. Acta*, 1989, **72**, 447; (b) T. Masquelin and D. Obrecht, *Tetrahedron Lett.*, 1994, **35**, 9387; (c) T. Masquelin and D. Obrecht, *Synthesis*, 1995, 276; (d) K. Utimoto, H. Miwa and H. Nozaki, *Tetrahedron Lett.*, 1981, **22**, 4277; (e) T. Masquelin and D. Obrecht, *Tetrahedron*, 1997, **53**, 641; (f) A. Degl Innocenti, P. Scalfato, A. Capperucci, L. Bartoletti, A. Mordini and G. Reginato, *Tetrahedron Lett.*, 1995, **36**, 9031; (g) D. S. Garvey, J. T. Wasicak, R. L. Elliott, S. A. Lebold, A.-M. Hettinger, G. M. Carrera, N.-H. Lin, Y. He, M. W. Holladay, D. J. Anderson, E. D. Cadman, J. L. Raskiewicz, J. P. Sullivan and S. P. Arneric, *J. Med. Chem.*, 1994, **37**, 4455; (h) M. Falorni, G. Giacomelli and A. M. Spanedda, *Tetrahedron: Asymmetry*, 1998, **9**, 3039.
- F. S. Al-Hajjar and S. S. Sabri, *J. Heterocycl. Chem.*, 1986, **23**, 727.
- R. J. Linderman and K. S. Kirolos, *Tetrahedron Lett.*, 1989, **30**, 2049.
- M. Falorni, G. Giacomelli and A. M. Spanedda, *Tetrahedron: Asymmetry*, 1999, **9**, 3039.
- (a) A. N. Kost and I. I. Grandberg, in *Advances in Heterocyclic Chemistry*, A. R. Katritzky, A. J. Boulton, Ed., Academic Press, New York, 1966, Vol. 6, p. 347; (b) W. Murray, M. Wachter, D. Barton and Y. Forero-Kelly, *Synthesis*, 1991, 18; (c) T. Nagai and M. Hamaguchi, *Org. Prep. Proced. Int.*, 1993, **25**, 403; (d) C. Kashima, H. Harada, I. Kita, I. Fukuchi and A. Hosomi, *Synthesis*, 1994, 61; (e) X.-j. Wang, J. Tan, K. Grozinger, R. Betageri, T. Kirrane and J. R. Proudfoot, *Tetrahedron Lett.*, 2000, **41**, 5321.
- Crystal data for **6d-3**: C₁₄H₁₇N₃O, *M* = 243.31, monoclinic, *a* = 10.922(2), *b* = 9.557(1), *c* = 13.551(3) Å, β = 113.20(1)°, *V* = 1300.0(4) Å³, space group *P2₁/c* (no. 14), *Z* = 4, *D*_{calc} = 1.243 g cm⁻³, *F*₀₀₀ = 520.00, μ (Mo-K α) = 0.81 cm⁻¹, 9135 reflections measured, 3028 unique (*R*_{int} = 0.031) which were used in all calculations. The final *wR* (*F*₂) was 0.071 (all data).
- (a) A. C. Veronse, R. Callegari, C. F. Morelli and C. B. Vicentini, *Tetrahedron*, 1997, **53**, 14497; (b) T. N. Mitchell, A. E.-Farargy, S.-N. Moschref and E. Gourzoulidou, *Synlett*, 2000, 223.
- D. S. Garvey, J. T. Wasicak, R. L. Elliott, S. A. Lebold, A.-M. Hettinger, G. M. Carrera, N.-H. Lin, Y. He, M. W. Holladay, D. J. Anderson, E. D. Cadman, J. L. Raskiewicz, J. P. Sullivan and S. P. Arneric, *J. Med. Chem.*, 1994, **37**, 4455.
- A. L. Zografos, C. A. Mitsos and O. Igglessi-Markopoulou, *Org. Lett.*, 1999, **1**, 1953.